NEW YORK--(BUSINESS WIRE)--Pfizer Inc. today issued the following statement regarding the voluntary recall of Lo/Ovral®-28 (norgestrel and ethinyl estradiol): We have announced a voluntary recall of Lo/Ovral®-28 (norgestrel and ethinyl estradiol) and Norgestrel and Ethinyl Estradiol Tablets (generic) birth control pills in the United States. We understand that this news can be very concerning and confusing for any woman who takes birth control pills to protect against unintended pregnancies. 

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. announced today that it has voluntarily recalled 14 lots of Lo/Ovral®-28 (norgestrel and ethinyl estradiol)Tablets and 14 lots of Norgestrel and Ethinyl Estradiol Tablets (generic)for customers in the U.S. market. An investigation by Pfizer found that some blister packs may contain an inexact count of inert or active ingredient tablets and that the tablets may be out of sequence. The cause was identified and corrected immediately. These products are oral co

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE):   ($ in millions, except per share amounts)   Fourth-Quarter(3)   Year-to-Date(3) 2011   2010   Change 2011   2010   Change Reported Revenues $ 16,746 $ 17,354 (4 %) $ 67,425 $ 67,057 1 % Adjusted Income(1) 3,863 3,744 3 % 18,217 17,885 2 % Adjusted Diluted EPS(1) 0.50 0.47 6 % 2.31 2.22 4 % Reported Net Income(2) 1,439 2,890 (50 %) 10,009 8,257 21 % Reported Diluted EPS(2) 0.19 0.36 (47 %) 1.27 1.02 25 %                                       S

LONDON--(BUSINESS WIRE)--Today, 13 pharmaceutical companies, the U.S., U.K. and U.A.E governments, the Bill & Melinda Gates Foundation, the World Bank and other global health organisations announced a new, coordinated push to accelerate progress toward eliminating or controlling 10 neglected tropical diseases (NTDs) by the end of the decade. Uniting efforts with NTD-endemic countries, partners pledged to bring a unique focus to defeating these diseases and to work together to improve the liv

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved INLYTA® (axitinib), a kinase inhibitor, for the treatment of patients with advanced renal cell carcinoma (RCC) after failure of one prior systemic therapy. The approval is based on data from the Phase 3 AXIS trial, which demonstrated that INLYTA significantly extended progression free survival (PFS) [HR=0.67, 0.54-0.81, P<0.0001] with a median PFS of 6.7 months (95% CI: 6.3, 8.

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for standard review of bosutinib as a treatment option for adult patients with previously treated Philadelphia chromosome positive (Ph+) chronic myeloid leukemia (CML). This submission was based on efficacy and safety data from Study 200, a single-arm study of bosutinib in over 500 patients with previously treated Ph+ CML, including patients resistan